IMMUNO-CHECKPOINT INHIBITORS INDUCED COLITIS TREATED WITH MESALAMINE

被引：0
|
作者：
Abu-Sbeih, Hamzah
Shuttlesworth, Gladis
Samdani, Rashmi
Zuazua, Rose
Wang, Yinghong
机构：
来源：
GASTROENTEROLOGY | 2018年 / 154卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P053
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [1] IMMUNO-CHECKPOINT INHIBITORS INDUCED COLITIS TREATED WITH MESALAMINE
    Abu-Sbeih, Hamzah
    Shuttlesworth, Gladis
    Samdani, Rashmi
    Zuazua, Rose
    Wang, Yinghong
    [J]. INFLAMMATORY BOWEL DISEASES, 2018, 24 : S19 - S19
  • [2] IMMUNO-CHECKPOINT INHIBITOR INDUCED COLITIS IN A PATIENT WITH LUNG CANCER AND COLON METASTASIS TREATED WITH MESALAMINE: A CASE STUDY
    Abu-Sbeih, Hamzah
    Shuttlesworth, Gladis
    Samdani, Rashmi
    Zuazua, Rose
    Wang, Yinghong
    [J]. GASTROENTEROLOGY, 2018, 154 (01) : S27 - S27
  • [3] IMMUNO-CHECKPOINT INHIBITOR INDUCED COLITIS IN A PATIENT WITH LUNG CANCER AND COLON METASTASIS TREATED WITH MESALAMINE: A CASE STUDY
    Abu-Sbeih, Hamzah
    Shuttlesworth, Gladis
    Samdani, Rashmi
    Zuazua, Rose
    Wang, Yinghong
    [J]. INFLAMMATORY BOWEL DISEASES, 2018, 24 : S19 - S19
  • [4] The role of immuno-checkpoint inhibitors in Hodgkin lymphoma
    Maruyama, Dai
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 31 - 31
  • [5] Immuno-checkpoint inhibitors in metastatic esophago-gastric cancer
    Schena, Marina
    Battaglia, Angelo F.
    Trogu, Antonio
    [J]. JOURNAL OF THORACIC DISEASE, 2019, 11 : S376 - S380
  • [6] SHORT TERM ENDOSCOPIC FOLLOW UP ON IMMUNO-CHECKPOINT INHIBITOR INDUCED COLITIS POST TREATMENT
    Ali, Faisal S.
    Abu-Sbeih, Hamzah
    Samdani, Rashmi
    Wang, Yinghong
    [J]. GASTROENTEROLOGY, 2018, 154 (01) : S53 - S54
  • [7] SHORT TERM ENDOSCOPIC FOLLOW UP ON IMMUNO-CHECKPOINT INHIBITOR INDUCED COLITIS POST TREATMENT
    Ali, Faisal S.
    Abu-Sbeih, Hamzah
    Samdani, Rashmi
    Wang, Yinghong
    [J]. INFLAMMATORY BOWEL DISEASES, 2018, 24 : S37 - S37
  • [8] PREVALENCE OF IMMUNORELATED MUSCULOSKELETAL ADVERSE EFFECTS IN PATIENTS WITH LUNG CANCER OR MELANOMA TREATED WITH IMMUNO-CHECKPOINT INHIBITORS
    Velasco, L. Salvatierra
    Sequero, S.
    Ubeda, J. Rubio
    Penalver, D. Martinez
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1769 - 1769
  • [9] Hyperprogression during immuno-checkpoint inhibitors (ICIs): A clinically significant problem?
    Fare, E.
    Sdao, S.
    Damian, S.
    Cresta, S.
    Del Vecchio, M.
    Di Bartolomeo, M.
    Di Guardo, L. A.
    Duca, M.
    Indini, A.
    Necchi, A.
    Niger, M.
    Prisciandaro, M.
    Procopio, G.
    Raggi, D.
    Verzoni, E.
    Pruneri, G.
    Di Nicola, M.
    de Braud, F. G. M.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [10] Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
    Revythis, Antonios
    Limbu, Anu
    Mikropoulos, Christos
    Ghose, Aruni
    Sanchez, Elisabet
    Sheriff, Matin
    Boussios, Stergios
    [J]. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (14)
12345